Kolkhir, Pavel http://orcid.org/0000-0001-5380-8132
Altrichter, Sabine http://orcid.org/0000-0001-9955-385X
Badloe, Fariza Mishaal Saiema
Belasri, Hafsa
Charles, Nicolas http://orcid.org/0000-0002-5416-5834
De Vriese, Shauni
Gutermuth, Jan
Huygen, Lisa
Kocatürk, Emek
Kortekaas Krohn, Inge http://orcid.org/0000-0003-3649-1131
Muñoz, Melba
Moñino-Romero, Sherezade
Reber, Laurent L. http://orcid.org/0000-0003-3384-6769
Scheffel, Jörg
Steinert, Carolin http://orcid.org/0000-0001-5661-3613
Xiang, Yi-Kui http://orcid.org/0000-0003-3432-6837
Maurer, Marcus http://orcid.org/0000-0002-4121-481X
Article History
First Online: 1 March 2024
Competing interests
: P.K. was a speaker and/or consultant for Novartis, Roche and ValenzaBio, outside of the submitted work. S.A. is a speaker and/or advisor for and/or has received research funding from Allakos, AstraZeneca, Biocryst, Blueprint, CSL Behring, Moxie, Novartis, Phavaris, Sanofi, Takeda and Thermo Fisher. N.C. has received consulting fees and/or research funding from Argenx and Onward Therapeutics. J.G. has received research grants from the Flemish Science foundation (FWO), Sanofi concerning autoreactive IgE, and was an advisor or speaker for Abbvie, Almirall, Ariez International, Eli-Lilly, Leo-Pharma and Pfizer. E.K. was a speaker and advisor for Novartis, Menarini, LaRoche Posey, Sanofi, Bayer, Abdi İbrahim and Pfizer. I.K.K. has received research funding from Fonds Wetenschappelijk Onderzoek (grant no. G056322N), AbbVie, Pfizer and Sanofi/Regeneron. M. Maurer has been a speaker and/or advisor for and/or has received research funding from Allakos, AstraZeneca, Blueprint, Takeda and Annexon. L.L.R. has received consulting fees and/or research funding from NEOVACS, Novartis, CEVA and Argenx. J.S. has conducted studies for and received research funds or was advisor for Allakos, Ascilion, AstraZeneca, CSL Behring, Celldex, Genentech, Escient, Novartis, Sanofi, Servier, Septerna, ThirdHarmonicBio, ThirdRock and ThermoFisher. M. Muñoz is or recently was a speaker and/or advisor for and/or has received research funding from Astria, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, GSK, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pfizer, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third Harmonic Bio, UCB and Uriach. The other authors declare no competing interests.